Since the World Health Organization (WHO) published its second and third reports on diabetes mellitus in 1980 and 1985, respectively,':' laboratory workers, diabetologists and, one hopes, other physicians, have developed an increased awareness of the need for adherence to a standardized protocol for the diagnosis of diabetes and impaired glucose tolerance. It is perhaps of greatest relevance when performing epidemiological studies and comparing one population with another, but it can also be of considerable importance to the individual who, on the results of an oral glucose tolerance test (GTI), is going to be classified as diabetic or non-diabetic with consequences that are likely to be life-long. There is, therefore, no room for variation in the way the GTI is performed, nor in the diagnostic criteria used for interpretation.
Despite the existence of detailed advice on how the GTI should be conducted,' there are still areas of ambiguity that require clarification, and an important one relates to the glucose load administered. There is now international agreement that 75 g of glucose should be used for adults, but there is no clear recommendation of the form this glucose should take, i.e. anhydrous or the, perhaps more commonly available, monohydrate.
In its first report in 1965, the WHO recommended monohydrate (then 50 g).' The 1980 and 1985 reports simply referred to 'glucose', but in later correspondence, WHO representatives have argued for 75 g of anhydrous glucose or 82·5 g of monohydrate." The American National Diabetes Data Group similarly made no specification in its _ recommendations.' This is a surprising omission as it makes a difference of about 10% in the dose of actual glucose administered and potentially is the easiest aspect of the test to control. Moreover, this ambiguity was found to be reflected in practice when a survey of GTT procedure was conducted amongst United Kingdom laboratories carrying out the test." Rather more than 50% appeared to be employing Correspondence: Dr K Wiener.
monohydrate but many were somewhat uncertain of the form they were using, especially when it was obtained pre-weighed and packaged from pharmacy departments or commercial sources. The same confusion existed when the dose was given as a partially hydrolysed starch preparation such as Lucozade, with several different volumes being administered. This is not the first time that this issue has been raised. It was raised in 1981 by Garcia-Webb' who calculated that a patient could be classified differently if using different types of glucose and recommended that 75 g of monohydrate should be used because it was cheaper and the stable crystalline form under normal conditions. Hindle and Rostron addressed the matter again in 1986 8 and Keen et al" argued in favour of 75 g of anhydrous glucose, as did Evans and Longland'" in 1988.
The confusion is increased by the British Pharmacopoeia using the terms 'Glucose' and 'Anhydrous glucose' to describe the monohydrous and anhydrous forms, respectively. Furthermore, the British National Formulary entry for the GTT refers to '75 g of glucose (dextrose monohydrate)'; however, this is under review.
Clearly, this issue needs to be resolved once and for all and, although I do not have strong views on which form should be employed, I do think there should be standardization and it seems to me that the WHO and International Diabetes Federation should consider the relevant arguments and aim to achieve international agreement and implementation without delay. Furthermore, it is essential that the decision and a definitive statement are widely publicized among clinical biochemists, diabetologists, general physicians, pharmacists and any other interested professional groups.
In tests such as the GTT which are susceptible to influence by many factors, it is imperative to standardize the procedure where possible and eliminate those sources of variability that can be identified.
